Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;7(5):286-94.
doi: 10.1038/nrneph.2011.26. Epub 2011 Mar 22.

MicroRNAs as mediators and therapeutic targets in chronic kidney disease

Johan M Lorenzen  1 , Hermann Haller, Thomas Thum
Affiliations
Review

MicroRNAs as mediators and therapeutic targets in chronic kidney disease

Johan M Lorenzen et al. Nat Rev Nephrol. 2011 May.

Abstract

Chronic kidney disease (CKD) is characterized by tubulointerstitial deposition of extracellular matrix, tubular atrophy and dilatation; the replacement of organ architecture by connective tissue results in progressive loss of organ function. Micro (mi)RNAs are important mediators of tissue fibrosis under various pathological conditions and are of potential therapeutic relevance. These short, noncoding nucleotides (∼22 bases) regulate target messenger RNAs at the post-transcriptional level. Several hundred miRNAs regulate a considerable amount of the human genome and are involved in virtually all biological processes, including cellular proliferation, apoptosis and differentiation. Thus, miRNA deregulation often results in impaired cellular function and development of disease. Here, we summarize the current knowledge on the role of miRNAs in CKD, with particular emphasis on hypertensive kidney disease, diabetic nephropathy, glomerular biology, and IgA nephropathy. Identification of miRNA regulation and function in renal pathology may pinpoint miRNAs as new therapeutic targets in kidney fibrosis and related diseases. A new class of RNA therapeutics, that is, miRNA modulators (such as antagomirs) have been developed, which enable specific targeting of miRNAs and respective downstream gene networks in vivo, thus influencing the mechanisms that underlie disease initiation or progression. The therapeutic potential of miRNA-based treatment strategies in CKD are discussed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9 - PubMed
    1. Am J Hypertens. 2010 Jan;23(1):78-84 - PubMed
    1. Dev Cell. 2004 May;6(5):719-28 - PubMed
    1. Cell. 1993 Dec 3;75(5):843-54 - PubMed
    1. Genes Dev. 2006 Mar 1;20(5):515-24 - PubMed